Understanding the Market | ESSEX BIO-TECH surged nearly 16% during the session, rising over 60% in the past month as Bevacizumab reached the primary clinical endpoint in Phase III
ESSEX BIO-TECH's stock price rose nearly 16% during the session, with a cumulative increase of over 60% since March 27. As of the time of writing, the stock price is up 11.52%, at HKD 4.55, with a trading volume of HKD 14.6944 million. The company's HLX04-O (Bevacizumab) has shown efficacy comparable to Ranibizumab and good safety in Phase III clinical trials in Chinese patients. An international multicenter Phase III clinical study is ongoing, with a new drug application expected to be submitted in 2025
According to Zhitong Finance APP, ESSEX BIO-TECH (01061) rose nearly 16% during the trading session, with a cumulative increase of over 60% since March 27. As of the time of writing, it has risen 11.52%, priced at HKD 4.55, with a transaction volume of HKD 14.6944 million.
In terms of news, ESSEX BIO-TECH announced at the beginning of the month that the phase III clinical study of HLX04-O (Bevacizumab) in Chinese patients showed that HLX04-O was non-inferior to Ranibizumab in terms of the average change in best corrected visual acuity (BCVA) from baseline at week 48, achieving the primary endpoint. HLX04-O and Ranibizumab exhibited similar overall, ocular, and non-ocular safety profiles in patients with wet AMD, demonstrating good safety. The international multicenter phase III clinical study is being conducted in several European countries, Australia, and the United States, with the last patient visit expected to be completed in January 2025. A new drug application is anticipated to be submitted in 2025.
It is reported that ESSEX BIO-TECH is collaborating with Junshi Biosciences to develop Bevacizumab. HLX04-O is a new ophthalmic formulation product developed based on Junshi Biosciences' independently developed Hanbeitai (Bevacizumab injection), optimized in terms of prescription, specifications, and production process according to the needs of ophthalmic medication, while maintaining the same active ingredient, intended for the treatment of wet AMD
